Evidence map›Paper›PMID 36993198›Full record

ArticleResearch square2023

Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.

John Lafin, Cinzia Scarpini, Armon Amini, Bendu Konneh, Jeffrey Howard, Thomas Gerald, Michelle Nuno, Jin Piao, Anna Savelyeva, Zhaohui Wang and 13 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

John LafinThe University of Texas Southwestern Medical Center.
Cinzia ScarpiniUniversity of Cambridge.
Armon AminiThe University of Texas Southwestern Medical Center.
Bendu KonnehThe University of Texas Southwestern Medical Center.
Jeffrey HowardThe University of Texas Southwestern Medical Center.
Thomas GeraldThe University of Texas Southwestern Medical Center.
Michelle NunoUniversity of Southern California.
Jin PiaoUniversity of Southern California.
Anna SavelyevaThe University of Texas Southwestern Medical Center.
Zhaohui WangThe University of Texas Southwestern Medical Center.
Jeffrey GaganThe University of Texas Southwestern Medical Center.
Liwei JiaThe University of Texas Southwestern Medical Center.
Cheryl LewisThe University of Texas Southwestern Medical Center.
Sarah MurrayUniversity of California, San Diego.
Yun SawaUniversity of California, San Diego.
Vitaly MargulisThe University of Texas Southwestern Medical Center.
Solomon WolduThe University of Texas Southwestern Medical Center.
Douglas StrandThe University of Texas Southwestern Medical Center.
Nicholas ColemanUniversity of Cambridge.
James AmatrudaUniversity of Southern California.
Lindsay FrazierDana-Farber/Boston Children's Cancer and Blood Disorders Center.
Matthew MurrayUniversity of Cambridge.
Aditya BagrodiaUniversity of California, San Diego.
The University of Texas Southwestern Medical Center · USUniversity of Southern California · USUniversity of California San Diego · USUniversity of Cambridge · GB

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell TumorsUH3CA240688 · NCI · DANA-FARBER CANCER INST · PI FRAZIER, ANNE LINDSAY · 2022 to 2024
$1.1M
NCI NIH HHS P30 CA142543NCI NIH HHS UH3 CA240688
6 · The paper itself

Abstract

Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) GCT pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine the serum miR-371a-3p assay in the minimal residual disease setting we compared performance of raw (Cq) and normalized (∆Cq, RQ) values from prior assays, and validated interlaboratory concordance by aliquot swapping. Revised assay performance was determined in a cohort of 32 patients suspected of occult retroperitoneal disease. Assay superiority was determined by comparing resulting receiver-operator characteristic (ROC) curves using the Delong method. Pairwise t-tests were used to test for interlaboratory concordance. Performance was comparable when thresholding based on raw Cq

Identifiers

PMID36993198
PMCPMC10055551
OpenAlexW4328131331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.